Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons

  title={Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons},
  author={Katelyn Chitwood and Jeremy Robert Etzkorn and George F. Cohen},
  journal={Dermatologic Surgery},
Background Topical chemotherapy, topical immunomodulators, or intralesional chemotherapy may be used to treat nonmelanoma skin cancer (NMSC). Objectives To review the cost and efficacy of topical and intralesional therapies for NMSC. Methods Literature search assessing the efficacy of NMSC treatment with topical imiquimod, topical 5‐flourouracil (5FU) intralesional 5FU, methotrexate, bleomycin, and interferon (IFN). Single‐lesion case reports were excluded. Aggregate cure rates and the… 

Figures and Tables from this paper

Intralesional therapy for the treatment of keratoacanthoma

The present study set out to review the current state of the art of the intralesional treatment of KA, which could be cosmetically and functionally a better alternative to surgical removal, while it provides similar outcomes.

Cryosurgery, Intralesional Methotrexate and Imiquimod for Keratoacanthoma: Tuning the Combination

It is suggested that the present three modalities combination (one session mild cryosurgery/low dose, 5 mg intralesional methotrexate and 2 weeks once daily imiquimod) is a promising treatment for KA that merits evaluation in further studies.

Topical Therapies for Nonmelanoma Skin Cancers

Topical therapies provide an alternative treatment modality for some skin cancer patients as well as serving as a useful adjunct to surgery, and may increase overall efficacy by treating subclinical lesions and identifying asymmetrical growth of NMSCs.

Immunocryosurgery for Nonmelanoma Skin Cancer: Applications and Practical Tips

The efficacy of immunocryosurgery signifies the potential of nonsurgical, combination approaches in the treatment of skin neoplasms and particularly of basal cell carcinoma.

Debulking followed by intralesional 5‐fluorouracil for the treatment of cutaneous squamous cell carcinoma and keratoacanthoma: A retrospective analysis

Treatment of cSCC and KA with deb‐IL5FU demonstrated high tumor clearance rates, and lower rates of clearance were seen in males, immunosuppressed patients, tumors located on the scalp and face/neck/ears.

A Non-Surgical and Cost-Effective Treatment Approach Employing Topical Imiquimod, 5-Fluorouracil, and Tretinoin for Primary Non-Melanoma Skin Cancers.

The combination of imiquimod/5-fluorouracil/tretinoin with cryotherapy with brief cryotherapy had high clearance rates and was the most effective treatment regimen.

Combination Topical Chemotherapy for the Treatment of an Invasive Cutaneous Squamous Cell Carcinoma

Topical combination therapy with imiquimod, 5-FU, and tretinoin with intermittent, brief cryotherapy effectively treated a small, invasive SCC in this select patient who deferred surgery.

Intralesional methotrexate in dermatology: Diverse indications and practical considerations

Dermatologists should consider using IL‐MTX for a range of recalcitrant cutaneous conditions, particularly for those patients not amenable to surgery or systemic therapy.

Intralesional and Perilesional Treatment of Skin Cancers

In the following chapter, various intralesional and perilesional agents that have been used in the treatment of skin cancers will be presented by practitioners familiar with their use to facilitate their use in practice and increase the variety of treatment options available to patients with cutaneous tumors.



Intralesional chemotherapy for nonmelanoma skin cancer: a practical review.

Treatment of Bowen's Disease with Topical 5% Imiquimod Cream: Retrospective Study

Topical 5% imiquimod cream appears to be clinically beneficial in the treatment of Bowen's disease and should be considered as a treatment option.

Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients.

The results demonstrate a high efficacy and a good tolerability of topical treatment of imiquimod 5% cream in BD in TR, which represents a promising new therapeutic modality for BD, especially on exposed areas such as the face and ears.

Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma: 12‐Week Open‐Label Trial

Treatment of superficial BCCs with topical imiquimod for 12 weeks produced an excellent clinical response overall, with complete remission maintained after a mean of 23 months of follow-up.

Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report

Results show that topical imiquimod can be an effective option for the conservative management of KA as previously reported and suggest that lesions treated with imiquIMod cream should be considered for biopsy to judge histopathological remission after 5 to 8 weeks of application to shorten the duration of the treatment.

Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy.

This trial demonstrates that intralesional interferon is effective in the treatment of small sun-induced squamous cell carcinomas with well-tolerated side effects and a highly acceptable cosmetic result.